dalteparin has been researched along with thromboplastin in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (8.70) | 18.2507 |
| 2000's | 28 (60.87) | 29.6817 |
| 2010's | 13 (28.26) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Brieger, D; Dawes, J | 1 |
| Béguin, S; Bendetowicz, AV; Caplain, H; Hemker, HC | 1 |
| Deckmyn, H; Lambeir, AM; Matthyssens, G; Nyström, A; Stassen, JM; Vermylen, J; Vreys, I | 1 |
| Fernández, JA; Griffin, JH; Petäjä, J | 1 |
| Ball, SP; Becker, RC; Benoit, S; Liu, L; Spencer, FA; Zhang, Q | 1 |
| Hayes, MG; Holmes, MB; Mann, KG; Schneider, DJ; Sobel, BE | 1 |
| Ahmad, S; Fareed, J; Jeske, WP; Ma, Q; Walenga, JM | 1 |
| Andreozzi, GM; Carraro, P; Cella, G; Fareed, J; Hoppensteadt, DA; Mazzaro, G; Motta, G; Sbarai, A | 1 |
| Fujishima, Y; Miyake, Y; Sukamoto, T; Yokota, K | 1 |
| Aoshima, K; Asakura, H; Ichino, T; Ito, T; Kato, M; Miyamoto, KI; Mizutani, T; Morishita, E; Nakao, S; Ontachi, Y; Saito, M; Suga, Y; Yamazaki, M; Yoshida, T | 1 |
| Carrasco, P; Montes, R; Pérez-Ruiz, A; Rocha, E | 1 |
| Baetta, R; Camera, M; Comparato, C; Ezekowitz, MD; Fuortes, M; Paoletti, R; Rossi, F; Toschi, V; Tremoli, E | 1 |
| Abbate, R; Falciani, M; Fedi, S; Gensini, GF; Gori, AM; Pepe, G; Prisco, D; Rogolino, A | 1 |
| Lindmark, E; Siegbahn, A | 1 |
| Aznar, J; Martinez-Sales, V; Oms, JG; Réganon, E; Vila, V | 1 |
| Borawski, J; Myśliwiec, M; Naumnik, B | 1 |
| Bijsterveld, NR; Büller, HR; Levi, M; Meijers, JC; Moons, AH; Peters, RJ | 1 |
| Chakroun, T; Depasse, F; Elalamy, I; Gerotziafas, GT; Samama, MM; Van Dreden, P | 1 |
| Mohamed, S; Mousa, SA | 1 |
| Chakroun, T; Elalamy, I; Gerotziafas, GT; Samama, MM | 1 |
| Blann, AD; Caine, GJ; Christodoulos, K; Harris, AL; Lip, GY | 1 |
| Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M | 1 |
| Elalamy, I; Gerasimidis, T; Gerotziafas, GT; Konstantinidis, K; Samama, MM; Verdy, E | 1 |
| Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E | 1 |
| Cloonan, ME; DiNapoli, M; Mousa, SA | 1 |
| Graff, J; Harder, S; Picard-Willems, B | 1 |
| Barbanti, M; Cerletti, C; de Gaetano, G; Di Fabio, G; Donati, MB; Maugeri, N | 1 |
| Fenyvesi, T; Giese, C; Hagedorn, A; Harenberg, J; Traeger, I | 1 |
| Ballard, NE; Bedard, PW; Hawley, AE; Kaila, N; Londy, FJ; Meier, TR; Myers, DD; Schaub, RG; Vlasuk, GP; Wakefield, TW; Wrobleski, SK; Zajkowski, PJ | 1 |
| Jensen, AL; Jensen, KH; Jessen, LR; Kjelgaard-Hansen, M; Kristensen, AT; Pedersen, LB; Wiinberg, B | 1 |
| Ammollo, CT; Colucci, M; Semeraro, F; Semeraro, N | 1 |
| Eikelboom, JW; Quinlan, DJ | 1 |
| Chiari, A; Hacker, S; Kozek-Langenecker, S; Schaden, E; Schober, A; Spiss, C | 1 |
| Endzinas, Z; Gerbutaviciene, R; Gerbutavicius, R; Griniūte, R; Kiudelis, M; Mickevicius, A; Pundzius, J | 1 |
| Echrish, H; Ettelaie, C; Gardiner, E; Greenman, J; Li, C; Madden, LA; Maraveyas, A | 1 |
| Kerk, N; Pöppelmann, B; Schneider, SW; Strozyk, EA | 1 |
| Amaya, M; Amirkhosravi, A; Davila, M; Francis, JL; Meyer, T; Mousa, SA; Robson, T | 1 |
| Axelman, E; Brenner, B; Nadir, Y; Norman, D; Peled, E; Rovitsky, A | 1 |
| Bauer, KA; Buchbinder, E; Bullock, A; Campigotto, F; Caughey, T; Eneman, J; Furie, B; Kessler, CM; Lenz, HJ; Liebman, HA; Mantha, S; Neuberg, D; Raghavan, V; Rosovsky, R; Zwicker, JI | 1 |
| Bonnet, F; Elalamy, I; Galea, V; Gerotziafas, GT; Hatmi, M; Marret, E; Papageorgiou, C; Robert, F; Spyropoulos, A; Vandreden, P | 1 |
| Bacher, P; Fareed, J; Hoppensteadt, D; Jeske, WP; Kaiser, PC; Lassen, MR; Misselwitz, F; Prechel, MM; Walenga, JM | 1 |
| Francart, S; Francis, CW; Gosselin, RC; Gudmundsdottir, BR; Hawes, E; Letertre, LR; Malmstrom, RE; Moll, S; Onundarson, PT; Skeppholm, M | 1 |
| Baumann Kreuziger, LM; Desai, UR; Mast, AE; Wood, JP | 1 |
| Chakroun, T; Elalamy, I; Gerotziafas, GT; Larsen, AK; Mbemba, E; Sassi, M; Van Dreden, P | 1 |
| Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AY; Meyer, G | 1 |
| Araldi, RP; D'Amélio, F; Gonzaga, V; Kerkis, I; Mendes, TB; Pagani, E; Policiquio, B; Prezoto, BC; Valverde, CW; Viana, M; Vigerelli, H | 1 |
10 trial(s) available for dalteparin and thromboplastin
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Topics: Adult; Antithrombin III; Dose-Response Relationship, Drug; Enoxaparin; Enzyme Activation; Factor Xa; Factor Xa Inhibitors; Heparin; Humans; Injections, Subcutaneous; Male; Single-Blind Method; Thrombin; Thromboplastin | 1994 |
Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Topics: Aged; Anticoagulants; Blood Coagulation; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Hemostatics; Heparin; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Peptide Fragments; Prospective Studies; Protein Precursors; Prothrombin; Renal Dialysis; Thromboplastin; Time Factors | 2003 |
The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes.
Topics: Aged; Angina, Unstable; Anticoagulants; Blood Coagulation; Enoxaparin; Factor Xa; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Prothrombin; Thromboplastin; Treatment Outcome | 2003 |
Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
Topics: Aged; Angioplasty; Blood Coagulation; Carotid Artery Diseases; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Nadroparin; Platelet Aggregation Inhibitors; Stents; Thrombelastography; Thromboplastin | 2007 |
A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Coagulants; Enoxaparin; Female; Fibrinolytic Agents; Fundoplication; Humans; Informed Consent; Intermittent Pneumatic Compression Devices; Intraoperative Care; Laparoscopy; Male; Postoperative Care; Postoperative Complications; Prospective Studies; Statistics, Nonparametric; Thromboplastin; Venous Thrombosis | 2010 |
Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion.
Topics: Aged; Dalteparin; Disease Progression; Female; Humans; Male; Middle Aged; Molecular Weight; Neoplasm Invasiveness; Pancreatic Neoplasms; Thromboplastin; Venous Thromboembolism | 2010 |
Increased heparanase level and procoagulant activity in orthopedic surgery patients receiving prophylactic dose of enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa; Female; Glucuronidase; Hip; Humans; Knee; Male; Middle Aged; Orthopedic Procedures; Thrombin; Thromboplastin; Thrombosis | 2012 |
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).
Topics: Aged; Aged, 80 and over; Anticoagulants; Cell-Derived Microparticles; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Neoplasms; Survival Analysis; Thromboembolism; Thromboplastin | 2013 |
Sustained release of tissue factor following thrombosis of lower limb trauma.
Topics: Achilles Tendon; Anticoagulants; Double-Blind Method; Female; Fractures, Bone; Heparin, Low-Molecular-Weight; Humans; Lower Extremity; Male; Middle Aged; Prospective Studies; Tendon Injuries; Thromboplastin; Time Factors; Venous Thromboembolism | 2014 |
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; P-Selectin; Predictive Value of Tests; Prospective Studies; Recurrence; Risk Factors; Thromboplastin; Time Factors; Tinzaparin; Venous Thromboembolism | 2017 |
36 other study(ies) available for dalteparin and thromboplastin
| Article | Year |
|---|---|
Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane).
Topics: Animals; Antithrombin III; Blood Coagulation Tests; Chromatography, Affinity; Chromatography, Gel; Enoxaparin; Factor Xa Inhibitors; Female; Half-Life; Injections, Intravenous; Injections, Subcutaneous; Oligosaccharides; Rabbits; Thromboplastin; Tissue Distribution | 1994 |
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Topics: Animals; Anticoagulants; Aprotinin; Arthropod Proteins; Cattle; Cricetinae; Drug Evaluation, Preclinical; Enoxaparin; Factor VIIa; Factor Xa Inhibitors; Factor XIa; Femoral Vein; Fibrinolytic Agents; Heparin; Hirudin Therapy; Humans; Intercellular Signaling Peptides and Proteins; Kallikreins; Male; Partial Thromboplastin Time; Peptides; Platelet Adhesiveness; Recombinant Proteins; Thromboplastin; Thrombosis | 1995 |
Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cattle; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Dextran Sulfate; Drug Synergism; Enoxaparin; Enzyme Activation; Factor V; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Humans; Nadroparin; Protein C; Sharks; Structure-Activity Relationship; Swine; Thromboplastin; Tinzaparin | 1999 |
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Topics: Angina, Unstable; Blood Platelets; Enoxaparin; Factor Xa; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Thromboplastin; Time Factors | 2000 |
Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy.
Topics: Blood Coagulation; Enoxaparin; Fibrinolytic Agents; Heparin; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Thromboplastin; Whole Blood Coagulation Time | 2000 |
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Topics: Blood Platelets; Dose-Response Relationship, Drug; Drug Interactions; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thromboplastin; Tirofiban; Tyrosine | 2001 |
Tissue factor pathway inhibitor release induced by defibrotide and heparins.
Topics: Adult; Anticoagulants; Endothelium, Vascular; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heparin; Humans; Lipoproteins; Male; Middle Aged; Nadroparin; Polydeoxyribonucleotides; Thrombomodulin; Thromboplastin | 2001 |
The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
Topics: Animals; Anticoagulants; Antithrombin III; Bleeding Time; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Disease Models, Animal; Disseminated Intravascular Coagulation; Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Factor Xa; Factor Xa Inhibitors; Heparin; Heparitin Sulfate; Kinetics; Male; Platelet Aggregation; Rats; Rats, Wistar; Risk Assessment; Thromboplastin | 2001 |
Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models.
Topics: Animals; Anticoagulants; Antithrombin III; Biomarkers; Blood Proteins; Dalteparin; Disseminated Intravascular Coagulation; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Factor X; Hemostasis; Isoquinolines; Kidney Glomerulus; Lipopolysaccharides; Male; Piperidines; Pyridines; Rats; Rats, Wistar; Tetrahydroisoquinolines; Thromboplastin | 2002 |
Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium.
Topics: Anticoagulants; Cells, Cultured; Endothelium, Vascular; Fibrinolysis; Gene Expression Regulation; Heparin; Heparin, Low-Molecular-Weight; Humans; Lipoproteins; Plasminogen Activator Inhibitor 1; Reverse Transcriptase Polymerase Chain Reaction; Thromboplastin; Tissue Plasminogen Activator; Umbilical Veins | 2002 |
Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin.
Topics: Animals; Anticholesteremic Agents; Anticoagulants; Aorta; cdc42 GTP-Binding Protein; Cells, Cultured; Cholesterol; Diet, Atherogenic; Endothelium, Vascular; Enoxaparin; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Hemorheology; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; I-kappa B Proteins; Indoles; Male; NF-kappa B; NF-KappaB Inhibitor alpha; Platelet Adhesiveness; Protein Prenylation; Protein Processing, Post-Translational; Rabbits; RNA, Messenger; Signal Transduction; Thrombophilia; Thromboplastin; Transcription, Genetic; Tumor Necrosis Factor-alpha; Umbilical Veins | 2002 |
Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration.
Topics: Adult; Aged; Angina, Unstable; Anticoagulants; Antithrombin III; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Humans; Lipoproteins; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Protein Precursors; Prothrombin; Thromboplastin; Tissue Plasminogen Activator | 2002 |
Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Cell Adhesion; Cells, Cultured; Coculture Techniques; Cytokines; Dalteparin; Enalapril; Endothelium, Vascular; Humans; Hypolipidemic Agents; Interleukin-10; Interleukin-6; Monocytes; Simvastatin; Thromboplastin; Tumor Necrosis Factor-alpha; U937 Cells | 2002 |
Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
Topics: Anticoagulants; Blood Coagulation; Cells, Cultured; Endothelium, Vascular; Enoxaparin; Heparin; Humans; Lipoproteins; Thromboplastin; von Willebrand Factor | 2003 |
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Topics: Anticoagulants; Blood Coagulation; Blood Platelets; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Humans; Kinetics; Peptide Fragments; Plasma; Polysaccharides; Prothrombin; Thrombin; Thromboplastin | 2004 |
Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Factor VIIa; Fibroblast Growth Factor 2; Heparin, Low-Molecular-Weight; Humans; Lipoproteins; Neovascularization, Physiologic; Thromboplastin; Tinzaparin; Umbilical Veins | 2004 |
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Enoxaparin; Fondaparinux; Humans; In Vitro Techniques; Kinetics; Polysaccharides; Thrombelastography; Thrombin; Thromboembolism; Thromboplastin; Time Factors; Venous Thrombosis | 2004 |
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; P-Selectin; Platelet Activation; Thromboplastin; Vascular Endothelial Growth Factor A | 2005 |
Evaluation of two experimental venous thrombosis models in the rat.
Topics: Animals; Blood Coagulation Tests; Chlorides; Disease Models, Animal; Female; Ferric Compounds; Hemostasis; Male; Nadroparin; Rats; Rats, Wistar; Regression Analysis; Sensitivity and Specificity; Thromboplastin; Thrombosis; Venous Thrombosis | 2005 |
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Jugular Veins; Ligation; Morpholines; Nadroparin; Polysaccharides; Rabbits; Random Allocation; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis | 2007 |
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
Topics: Alanine; Cell Line, Tumor; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oxazoles; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombelastography; Thromboplastin; Thrombosis; Tinzaparin | 2007 |
Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Topics: Adult; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Daboia; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Naphthalenes; Partial Thromboplastin Time; Polysaccharides; Propionates; Thromboplastin; Viper Venoms | 2007 |
Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents; Blood Platelets; CD11b Antigen; CD40 Antigens; Cell Adhesion; Collagen; Dose-Response Relationship, Drug; Enoxaparin; Fibrinogen; Heparin, Low-Molecular-Weight; Humans; In Vitro Techniques; Leukocytes; P-Selectin; Peptide Fragments; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Stress, Mechanical; Thrombin; Thromboplastin | 2007 |
Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Topics: Anticoagulants; Blood Coagulation Tests; Dalteparin; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Humans; Oligosaccharides; Polysaccharides; Prothrombin; Thromboplastin | 2007 |
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Platelets; Disease Models, Animal; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hydroxyquinolines; Iliac Vein; Inflammation; Injections, Subcutaneous; Male; P-Selectin; Papio anubis; Phlebography; Thromboplastin; Time Factors; Ultrasonography, Doppler, Color; Vascular Patency; Venous Thrombosis | 2008 |
In vitro heparinization of canine whole blood with low molecular weight heparin (dalteparin) significantly and dose-dependently prolongs heparinase-modified tissue factor-activated thromboelastography parameters and prothrombinase-induced clotting time.
Topics: Animals; Anticoagulants; Blood Coagulation; Dalteparin; Dogs; Dose-Response Relationship, Drug; Female; Heparin Lyase; Kaolin; Male; Thrombelastography; Thromboplastin | 2008 |
Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins.
Topics: Antibodies; Carboxypeptidase B2; Cells, Cultured; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolysis; Fibrinolytic Agents; Heparin; Humans; Lipopolysaccharides; Monocytes; Thrombin; Thromboplastin; Time Factors; Tissue Plasminogen Activator | 2009 |
Low-molecular-weight heparin as an adjunct to thrombolysis in ST elevation myocardial infarction.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Routes; Electrocardiography; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infarction; Secondary Prevention; Thrombolytic Therapy; Thromboplastin; Treatment Outcome | 2009 |
Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
Topics: Adult; Anticoagulants; Blood Coagulation Tests; Drug Monitoring; Enoxaparin; Female; Humans; Male; Middle Aged; Thrombelastography; Thromboplastin | 2010 |
The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
Topics: Anticoagulants; Cell Line, Tumor; Endothelial Cells; Enoxaparin; Flow Cytometry; Heparin; Heparin, Low-Molecular-Weight; Humans; Melanoma; Prothrombin; RNA, Small Interfering; Skin Neoplasms; Thrombin; Thromboplastin; Tinzaparin; von Willebrand Factor | 2010 |
Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis.
Topics: Animals; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Cell Line, Tumor; Enoxaparin; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Neoplasms, Experimental; Platelet Aggregation Inhibitors; Thromboplastin; Warfarin | 2010 |
Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Cell-Derived Microparticles; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Postoperative Period; Thrombin; Thrombophilia; Thromboplastin | 2013 |
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Topics: Anticoagulants; Blood Coagulation Tests; Blood Donors; Calibration; Dabigatran; Enoxaparin; Factor X; Female; Fondaparinux; Heparin; Humans; International Normalized Ratio; Male; Polysaccharides; Prothrombin; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thromboplastin; Warfarin | 2016 |
Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Topics: Anticoagulants; Antithrombins; Blood Coagulation; Dalteparin; Enoxaparin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Lipoproteins; Polysaccharides; Thromboplastin | 2016 |
The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Ovarian Neoplasms; Plasma; Prothrombin; Thrombin; Thromboplastin; Tinzaparin | 2017 |
Advanced cell therapy with low tissue factor loaded product NestaCell® does not confer thrombogenic risk for critically ill COVID-19 heparin-treated patients.
Topics: Cell- and Tissue-Based Therapy; Clinical Trials as Topic; COVID-19; Critical Illness; Enoxaparin; Heparin; Humans; Pandemics; Thromboplastin | 2022 |